Akero Therapeutics Inc. (NASDAQ:AKRO) saw an upside of 2.49% to close Friday at $46.37 after adding $1.13 on the day. The 5-day average trading volume is 506,640 shares of the company’s common stock. It has gained $48.86 in the past week and touched a new high 2 times within the past 5 days. An average of 548,505 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 653,062.
AKRO’s 1-month performance is 4.90% or $1.57 on its low of $40.74 reached on 07/27/23. The company’s shares have touched a 52-week low of $10.48 and high of $58.38, with the stock’s rally to the 52-week high happening on 06/13/23. YTD, AKRO has lost -15.39% or -$8.43 and has reached a new high 3 times. However, the current price is down -20.58% from the 52-week high price.
Insider Transactions
AKRO stock investors last saw insider trading activity on Sep 19.Cheng Andrew (President and CEO) most recently sold 25,000 shares at $43.15 per share on Aug 01. This transaction cost the insider $1,078,867. President and CEO, Cheng Andrew, sold 25,000 shares at a price of $44.88 on Jul 03. Then, on Jun 23, Chief Development Officer Yale Catriona sold 11,000 shares at a price of $50.76 per share. This transaction amounted to $558,360.
Valuation Metrics
AKRO stock has a beta of -0.91. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 3.90.
Akero Therapeutics Inc.’s quick ratio for the period ended June 30 was 29.80, with the current ratio over the same period at 29.80. As well, the company’s long term debt to equity for the quarter ending June 30 was 0.04, while the total debt to equity was 0.04.
Earnings Surprise
For the quarterly period ending June 30 this year, Net income grew 11.84% to -$31.08 million, while revenue of -$25.83 million was 16.89% off the previous quarter. Analysts expected AKRO to announce -$0.63 per share in earnings in its latest quarter, but it posted -$0.6, representing a 4.80% surprise. AKRO stock balance sheet for the quarter ending June 30 shows that total liabilities totaled 47.37 million, with total debt at $26.18 million. Shareholders hold equity totaling $55.6 million.
Let’s look briefly at Akero Therapeutics Inc. (AKRO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 57.76% to suggest the stock is trending Neutral, with historical volatility in this time period at 42.19%.
The stock’s 5-day moving average is $46.57, reflecting a -2.49% or -$1.18 change from its current price. AKRO is currently trading +6.10% above its 20-day SMA, +18.88% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -8.91% and SMA200 by+9.71%.
Stochastic %K and %D was 61.18% and 69.03% and the average true range (ATR) pointed at 1.91. The RSI (14) points at 55.15%, while the 14-day stochastic is at 65.47% with the period’s ATR at 1.90. The stock’s 9-day MACD Oscillator is pointing at 0.28 and 0.88 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Akero Therapeutics Inc. (NASDAQ: AKRO), Morgan Stanley upgraded it to an Overweight rating. They previously had an Equal-weight rating on the stock. Analysts offering their rating for AKRO stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate AKRO as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 7 have offered a “buy” rating.
What is AKRO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $49.00 and a high of $70.00, with their median price target at $60.00. Looking at these predictions, the average price target given by analysts is for Akero Therapeutics Inc. (AKRO) stock is $60.00.
